The Effects of HMB, ATP, and HMB Plus ATP on Muscle Mass, Strength, and Power in Resistance Trained Athletes

This study has been completed.
Sponsor:
Collaborator:
University of Tampa
Information provided by (Responsible Party):
Metabolic Technologies Inc.
ClinicalTrials.gov Identifier:
NCT01508338
First received: January 9, 2012
Last updated: March 17, 2014
Last verified: March 2014
  Purpose

The purpose of this study is to

  • determine the effects of 12 weeks of HMB free acid gel, ATP, and HMB free acid gel plus ATP supplementation in trained individuals during a periodized training program on skeletal muscle hypertrophy, body composition, strength, force, velocity, and peak power during loaded and unloaded vertical jumps.

Additionally, the study will determine if either supplementation protocol prevents the typical decay seen in performance following an overreaching cycle performed in the 9th and 10th weeks of the study.

Finally, the study will elucidate the mechanisms of action of supplementation on protein breakdown by analyzing serum indices of muscle damage (CK, LDH) and anabolic status (Testosterone:Cortisol ratio) as well as a urinary indicator of protein breakdown (3-methylhistidine).

We hypothesize that under these conditions that the supplementation protocols will augment skeletal muscle hypertrophy, strength, and power and that HMB will blunt increases in serum indices of muscle damage, and urinary indices of protein breakdown.


Condition Intervention
Healthy Experienced Weight Training Males
Dietary Supplement: Placebo
Dietary Supplement: HMB
Dietary Supplement: Peak ATP and HMB
Dietary Supplement: ATP

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
Official Title: The Effects of HMB, ATP, and HMB Plus ATP on Muscle Mass, Strength, and Power in Resistance Trained Athletes

Further study details as provided by Metabolic Technologies Inc.:

Primary Outcome Measures:
  • Increased muscle strength, force, and power after intense weight training [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Increased muscle hypertrophy [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Enrollment: 44
Study Start Date: January 2012
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Dietary Supplement: Placebo
An oral placebo capsule will be taken each morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.
Experimental: HMB Dietary Supplement: HMB
A placebo capsule will be taken each morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.
Experimental: ATP and HMB Dietary Supplement: Peak ATP and HMB
One capsule containing 400 mg of Peak ATP will be taken in the morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.
Experimental: ATP Dietary Supplement: ATP
One capsule containing 400 mg of Peak ATP will be taken daily in the morning for 12 weeks.

Detailed Description:

In a randomized and double blind study the subjects will consume either placebo supplements, HMB supplement, ATP supplement, or HMB plus ATP supplements for 12 weeks. While consuming the supplements the subjects will undergo an extensive resistance training program designed to train all major muscle groups. An additional overreaching training cycle during weeks 9 and 10 which will involve a high-volume, hypertrophy style training program.

Subject testing will consist of the following:

  • Strength and power at weeks 0, 1, 4, 8, 9, 10, and 12
  • Range of motion and muscle soreness at weeks 0, 1, 8, 9, and 10
  • Body composition and muscle assessments at weeks 0, 1, 4, 8, 9, 10, and 12
  • Body fat assessments at weeks 0, 4, 8, and 12
  • Blood biochemical measurements at weeks 0, 1, 4, 8, 9, 10, and 12
  • Urinary analysis for protein breakdown (3-methylhistidine) at 0, 1, 8, 9, and 10 weeks
  Eligibility

Ages Eligible for Study:   18 Years to 30 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Subjects must meet all of the inclusion criteria to participate in the study.

  • Have 3 years minimum of free weight training experience
  • Can squat a minimum of 1.5 times their bodyweight
  • Can bench press a minimum equal to their bodyweight
  • Can deadlift a minimum of 1.5 times their bodyweight
  • Are free of musculoskeletal injuries
  • Have not taken creatine or HMB supplements for 6 weeks
  • Are not taking amino acid supplements
  • Are not using anabolic or catabolic hormones
  • Are not taking medications that may interfere with study measurements
  • Are not users of tobacco products

All candidates meeting any one of the exclusion criteria will not be enrolled into the study.

  • Do not have 3 years minimum of free weight training experience
  • Can not squat a minimum of 1.5 times their bodyweight
  • Can not bench press a minimum equal to their bodyweight
  • Can not deadlift a minimum of 1.5 times their bodyweight
  • Are not free of musculoskeletal injuries
  • Have not taken creatine or HMB supplements in the past 6 weeks
  • Are currently taking amino acid supplements
  • Are using anabolic or catabolic hormones
  • Are taking medications that may interfere with study measurements
  • Use of tobacco products
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01508338

Locations
United States, Florida
University of Tampa
Tampa, Florida, United States, 33606
Sponsors and Collaborators
Metabolic Technologies Inc.
University of Tampa
Investigators
Study Director: John A Rathmacher, PhD Metabolic Technologies Inc.
  More Information

No publications provided

Responsible Party: Metabolic Technologies Inc.
ClinicalTrials.gov Identifier: NCT01508338     History of Changes
Other Study ID Numbers: MTI2012-CS01
Study First Received: January 9, 2012
Last Updated: March 17, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Metabolic Technologies Inc.:
HMB beta-hydroxy-beta-methylbutyrate
ATP (adenosine-triphosphate)
trained athletes

ClinicalTrials.gov processed this record on October 22, 2014